{"database": "lobbying", "table": "lobbying_activities", "is_view": false, "human_description_en": "where filing_period = \"third_quarter\", filing_year = 2014 and issue_code = \"PHA\" sorted by filing_year descending", "rows": [[1549209, "8e982702-3f7a-4d33-a392-5982e9fae86f", "3T", "DICKSTEIN SHAPIRO LLP", 12208, "VERIMED, LLC", 2014, "third_quarter", "PHA", "Monitor legislative and administrative action regarding prescription drug abuse and diversion policies. \nH.R. 4486, Military Construction Veterans Affairs and Related Agencies Appropriations Act, 2015.\nDraft, Senate Military Construction Veterans Affairs and Related Agencies  Appropriations Act, 2015.\nS. 2450, Veterans' Access to Care through Choice, Accountability, and Transparency Act of 2014.", "Drug Enforcement Administration (DEA),HOUSE OF REPRESENTATIVES,SENATE,Veterans Affairs, Dept of (VA)", 10000, null, 0, 1, "2014-07-11T22:41:11.567000-04:00"], [1581051, "83b8ae7f-62ef-4cbf-9f20-c4b968460265", "3T", "CYBER SECURITY RESEARCH CONSULTANTS, LLC", 91694, "PDFRAZER CONSULTING INC CANADIAN INTERNATIONAL PHARMACY ASSOCIATION", 2014, "third_quarter", "PHA", "Monitoring Drug Importation Legislation FY 15 Agriculture Appropriations Bills", "HOUSE OF REPRESENTATIVES", 15000, null, 0, 1, "2014-09-22T07:46:43.450000-04:00"], [1581533, "0c714982-b3c0-4542-8e5a-0c4c017333bf", "Q3", "AMERICAN COLLEGE OF CLINICAL PHARMACY", 57258, "AMERICAN COLLEGE OF CLINICAL PHARMACY", 2014, "third_quarter", "PHA", "Coverage for direct patient care services of qualified pharmacists under Medicare and other public health programs.", "Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE", null, 145515, 0, 0, "2014-10-02T15:46:34.253000-04:00"], [1581736, "4c7e2482-a3e6-4920-a7ba-d5311207e1a1", "Q3", "MR. JOHN COSTER", 401103305, "AMERISOURCE BERGEN", 2014, "third_quarter", "PHA", "HR 800, S. 806, HR 4709, Ensuring Patient Access and Effective Drug Enforcement Act of 2014", null, 7500, null, 0, 0, "2014-10-05T09:39:18.210000-04:00"], [1581740, "23e5c289-84a1-4c09-995e-41080f75aba0", "Q3", "MR. JOHN COSTER", 401103305, "AMERICAN SOCIETY OF HEALTH SYSTEM PHARMACISTS", 2014, "third_quarter", "PHA", "Pharmacy provider status issues, particularly HR 4190, Medicare Coverage of Pharmacy Services", "White House Office", 13500, null, 0, 0, "2014-10-05T10:01:21.387000-04:00"], [1581742, "be5ec638-e1c1-4ebe-81da-b23fe2425f2f", "3A", "MR. JOHN COSTER", 401103305, "AMERISOURCE BERGEN", 2014, "third_quarter", "PHA", "HR 800, S. 806, HR 4709, Ensuring Patient Access and Effective Drug Enforcement Act of 2014", null, 15000, null, 0, 0, "2014-10-05T10:02:22.187000-04:00"], [1581746, "fb93eec4-0199-4de7-acb4-39f3d07de59c", "Q3", "MR. JOHN COSTER", 401103305, "HORIZON GOVERNMENT AFFAIRS", 2014, "third_quarter", "PHA", "medication therapy management legislation,particulary HR 1024 and S 557", null, 7500, null, 0, 0, "2014-10-05T10:11:25.143000-04:00"], [1581787, "2184dfa3-b84c-433c-86c0-35428611fc6c", "Q3", "INJURED WORKERS PHARMACY", 400765309, "INJURED WORKERS PHARMACY", 2014, "third_quarter", "PHA", "n/a", "HOUSE OF REPRESENTATIVES,SENATE", null, null, 0, 0, "2014-10-06T08:58:44.930000-04:00"], [1582038, "a0e193af-7ae1-4196-b869-c9177318bb25", "3A", "AMERICAN COLLEGE OF CLINICAL PHARMACY", 57258, "AMERICAN COLLEGE OF CLINICAL PHARMACY", 2014, "third_quarter", "PHA", "Coverage for direct patient care services of qualified pharmacists under Medicare and other public health programs.", "Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE", null, 145515, 0, 0, "2014-10-06T15:48:08.340000-04:00"], [1582052, "d63966d0-673e-4d77-ab6c-7da99e75d932", "Q3", "RED+BLUE STRATEGIES", 400693064, "EXPRESS SCRIPTS INC.", 2014, "third_quarter", "PHA", "H.R. 1367 - FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act - focused on policies that would negatively impact access to mail order pharmacy. \n\nRules, regulations and guidance specific to prescription drug pricing, generic utilization, biosimilars and specialty pharmacy. \n\nPolicies related to stopping the diversion of prescription medications in the nation's drug supply chain. \n\nChanges in naming policies for upcoming biosimilars. \n\nACA-related regulations impacting new rules for Exchanges specific to the promulgation of the prescription drug benefit. \n\nIssues regarding prescription drug coverage for public benefit programs. \n\nIssues related to Part D coverage for Medicare beneficiaries in hospice care.", "Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE", 60000, null, 0, 0, "2014-10-06T16:04:11.580000-04:00"], [1582656, "7bfe79f6-35d8-4b3b-8c55-fd98d31ec69c", "Q3", "KENT & O'CONNOR, INC.", 21426, "INTERNATIONAL WAREHOUSE LOGISTICS ASSOCIATION", 2014, "third_quarter", "PHA", "Legislation and regulations relating to drug safety issues.", "Consumer Product Safety Commission (CPSC),Environmental Protection Agency (EPA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),SENATE,Surface Transportation Board (STB),Transportation, Dept of (DOT),Transportation Security Administration (TSA),U.S. Customs & Border Protection", 30000, null, 0, 0, "2014-10-08T11:45:17.283000-04:00"], [1583065, "fd70eea3-2930-4807-be10-ecdbd3aa1096", "Q3", "CHAMBER HILL STRATEGIES", 400645947, "AMAG PHARMACEUTICALS (FORMERLY KNOWN AS LUMARA PHARMACEUTICAL)", 2014, "third_quarter", "PHA", "Implementation issues related to P.L. 113-54, the Drug Quality and Security Act", "Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE", 60000, null, 0, 0, "2014-10-08T17:27:21-04:00"], [1583136, "15212594-71f6-4918-8f43-166da5f1e84e", "Q3", "HEARTLAND SOLUTIONS GROUP, INC.", 312133, "ZEBRA TECHNOLOGIES CORPORATION", 2014, "third_quarter", "PHA", "Any and all issues related to labeling of generic drugs.", "HOUSE OF REPRESENTATIVES,SENATE", 9000, null, 0, 0, "2014-10-09T01:42:56.270000-04:00"], [1583228, "d7ab3609-2a8c-43e8-9b5c-fc088082b15a", "Q3", "RED+BLUE STRATEGIES", 400693064, "PEW CHARITABLE TRUSTS", 2014, "third_quarter", "PHA", "H.R. 3742 - Antibiotic Development to Advance Patient Treatment Act - ensuring that the pipeline for antibiotics is development in the country. \n\nOther issues related to improving availability and access to new antibiotics.\n\nIssues related to prescription drug abuse in the Medicare and Medicaid programs.", "Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE", 30000, null, 0, 0, "2014-10-09T10:38:45.543000-04:00"], [1583424, "ff4b5d3b-9b7a-416e-a79f-2981cd5cb6f0", "Q3", "ROCK & ASSOCIATES", 33545, "BRAIDWOOD MANAGEMENT, INC.", 2014, "third_quarter", "PHA", "Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation yet.", "HOUSE OF REPRESENTATIVES,SENATE", 11250, null, 0, 0, "2014-10-09T14:17:05.490000-04:00"], [1583443, "0169a0a6-e703-47fa-a98f-3c3fb8496d67", "Q3", "ROCK & ASSOCIATES", 33545, "CAPITOL HILL CONSULTING GROUP (ON BEHALF OF WELLNESS PHARMACY)", 2014, "third_quarter", "PHA", "Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation yet.", "HOUSE OF REPRESENTATIVES,SENATE", null, null, 0, 0, "2014-10-09T14:27:13.007000-04:00"], [1583448, "4026feaf-0bf9-4513-ae06-88257dfd96bd", "Q3", "ROCK & ASSOCIATES", 33545, "DIAMONDBACK DRUGS", 2014, "third_quarter", "PHA", "Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation yet.", "HOUSE OF REPRESENTATIVES,SENATE", 11250, null, 0, 0, "2014-10-09T14:32:14.040000-04:00"], [1583479, "ac81a849-c80d-4d29-af66-001d5e79a7a6", "Q3", "ROCK & ASSOCIATES", 33545, "TOWN & COUNTRY COMPOUNDING AND CONSULTING", 2014, "third_quarter", "PHA", "Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation yet.", "HOUSE OF REPRESENTATIVES,SENATE", 11250, null, 0, 0, "2014-10-09T14:53:21.923000-04:00"], [1583498, "45ea663b-f12f-4308-8277-0a567d62fde4", "Q3", "ROCK & ASSOCIATES", 33545, "US COMPOUNDING", 2014, "third_quarter", "PHA", "Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation yet.", "HOUSE OF REPRESENTATIVES,SENATE", 11250, null, 0, 0, "2014-10-09T14:59:25.613000-04:00"], [1583513, "c3495503-a165-4434-82f9-60c698bc00cb", "Q3", "ROCK & ASSOCIATES", 33545, "VETERINARY PHARMACIES OF AMERICA, INC.", 2014, "third_quarter", "PHA", "Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation yet.", "HOUSE OF REPRESENTATIVES,SENATE", 11250, null, 0, 0, "2014-10-09T15:04:29.397000-04:00"], [1583531, "8fc93e38-9904-41a5-bfa0-74696176f5b2", "Q3", "ROCK & ASSOCIATES", 33545, "WEDGEWOOD VILLAGE PHARMACY, INC.", 2014, "third_quarter", "PHA", "Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation yet.", "HOUSE OF REPRESENTATIVES,SENATE", 11250, null, 0, 0, "2014-10-09T15:10:32.227000-04:00"], [1583537, "c354c035-896f-436a-96f8-13d5f3daf7a3", "Q3", "ROCK & ASSOCIATES", 33545, "WOMEN'S INTERNATIONAL PHARMACY", 2014, "third_quarter", "PHA", "Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation yet.", "HOUSE OF REPRESENTATIVES,SENATE", 11250, null, 0, 0, "2014-10-09T15:15:34.007000-04:00"], [1583628, "65332d30-4a89-49e6-90e3-ce69c1bcb67d", "3A", "RED+BLUE STRATEGIES", 400693064, "PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA)", 2014, "third_quarter", "PHA", "Policies related to stopping prescription medication diversion and abuse\n\nIssues related to the creation of a biosimilar marketplace in the United States\n\nIssues related to home delivery of prescription drugs\n\nIssues related to Part D coverage for Medicare beneficiaries in hospice care", "HOUSE OF REPRESENTATIVES,SENATE", 60000, null, 0, 0, "2014-10-09T16:50:00.180000-04:00"], [1583808, "ff36adb4-e728-40f8-ab16-1133d6e3ee72", "Q3", "CHRISTY ELLERBEE CONSULTING, LLC", 401103332, "INDIVIOR, PLC (FKA RECKITT BENCKISER PHARMACEUTICALS, INC.)", 2014, "third_quarter", "PHA", "Pharmaceutical issues relevant to Reckitt Benckiser Pharmaceuticals, Inc.", "HOUSE OF REPRESENTATIVES,SENATE", null, null, 0, 0, "2014-10-10T10:40:58.813000-04:00"], [1583814, "59423de5-09e1-4fe5-89de-d3285ee24553", "Q3", "ENDO INTERNATIONAL", 40011075, "ENDO INTERNATIONAL", 2014, "third_quarter", "PHA", "Issues related to tamper resistant formulation of pharmaceutical drugs; Life Sciences Jobs and Investment Act.", "HOUSE OF REPRESENTATIVES,SENATE", null, 270000, 0, 0, "2014-10-10T10:54:03.427000-04:00"], [1584022, "eb9f9e19-1dd6-460c-84e3-f18c1429b6bd", "Q3", "PARRY, ROMANI, DECONCINI & SYMMS", 30792, "POZEN, INC.", 2014, "third_quarter", "PHA", "Support H.R.2985, The Combination Drug Development Incentive Act of 2013, to provide incentives for new drug development.", "HOUSE OF REPRESENTATIVES,SENATE", 36000, null, 0, 0, "2014-10-10T14:38:20.850000-04:00"], [1584112, "5f94be72-f6fc-4715-89f9-681cbbdf4319", "Q3", "CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.", 8511, "AMERICAN SOCIETY OF HEMATOLOGY", 2014, "third_quarter", "PHA", "HR 460, Patient Access to Treatment Act; HR 1801 Cancer Drug Coverage Parity Act/S. 1879 Cancer Treatment Parity Act.", "Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE", 30000, null, 0, 0, "2014-10-10T16:01:39.557000-04:00"], [1584133, "f8451ea1-e59f-403a-b3af-fe9a501c1704", "Q3", "CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.", 8511, "THE HEMOPHILIA ALLIANCE", 2014, "third_quarter", "PHA", "issues related to the 340B drug discount program", "Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE", 30000, null, 0, 0, "2014-10-10T16:18:46-04:00"], [1584153, "432abe85-89c6-4f26-b770-d7f697ab407a", "Q3", "CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.", 8511, "NATIONAL HEMOPHILIA FOUNDATION", 2014, "third_quarter", "PHA", "Issues related to hemophilia treatments, specialty pharmacies and the 340B drug purchasing program.\nHR 460 Patients Access to Treatment Act", "Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),Office of Management & Budget (OMB),SENATE", 50000, null, 0, 0, "2014-10-10T16:38:48.617000-04:00"], [1584187, "302ca5d6-5052-4244-9f8f-73d1f0be1b64", "Q3", "CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.", 8511, "NATIONAL ASSOCIATION OF EPILEPSY CENTERS", 2014, "third_quarter", "PHA", "Issues related to anti-epileptic drugs", "Agency for Healthcare Research & Quality (AHRQ),Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE", 10000, null, 0, 0, "2014-10-10T17:01:55.487000-04:00"], [1584207, "7a30a25e-b762-424f-94aa-12979680e39e", "Q3", "THE D MAJOR GROUP", 401103162, "CVS CAREMARK", 2014, "third_quarter", "PHA", "Issues concerning prescription drug abuse including H.R. 3392, The Medicare Part D Patient Safety & Drug Abuse Prevention Act; and H.R. 4069, The Ensuring Patient Access & Effective Drug Enforcement Act of 2014.", "HOUSE OF REPRESENTATIVES,SENATE", 30000, null, 0, 0, "2014-10-10T18:31:08.893000-04:00"], [1584223, "92b261d3-97f2-4bba-89f1-0ed785525b45", "Q3", "THE D MAJOR GROUP", 401103162, "HEALTH CARE SUPPLY CHAIN ASSOCIATION", 2014, "third_quarter", "PHA", "Implementation issues concerning the Drug Quality and Supply Act.", "HOUSE OF REPRESENTATIVES,SENATE", 30000, null, 0, 0, "2014-10-10T18:57:12.417000-04:00"], [1584544, "f8110fc5-8761-47a0-bc53-6bdc75ba1639", "Q3", "ASSOCIATION OF NATIONAL ADVERTISERS, INC.", 4653, "ASSOCIATION OF NATIONAL ADVERTISERS, INC.", 2014, "third_quarter", "PHA", "Proposals relating to the regulation of direct to consumer prescription drug advertising", "Commerce, Dept of (DOC),Federal Trade Commission (FTC),HOUSE OF REPRESENTATIVES,Natl Telecommunications & Information Administration (NTIA),SENATE", null, 350000, 0, 0, "2014-10-13T14:47:09.270000-04:00"], [1585471, "ec6ff3ac-30ba-4925-8db2-33922cf28263", "Q3", "VORYS ADVISORS, LLC", 400873558, "AMERISOURCEBERGEN CORPORATION", 2014, "third_quarter", "PHA", "Various health care proposals", "HOUSE OF REPRESENTATIVES", null, null, 0, 0, "2014-10-14T13:31:50.427000-04:00"], [1585782, "d8337ee6-301a-4080-9e29-d52b5b6841d8", "Q3", "RED+BLUE STRATEGIES", 400693064, "BLUE CROSS BLUE SHIELD OF MASSACHUSETTS", 2014, "third_quarter", "PHA", "Issues related to opioid abuse and programs that can successfully combat the problem.", "Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE", 60000, null, 0, 0, "2014-10-14T15:21:45.027000-04:00"], [1585830, "fb8bf7e4-5cb6-4dc3-9eae-88a616835f55", "Q3", "BROWN RUDNICK LLP", 287895, "AMNEAL PHARMACEUTICALS", 2014, "third_quarter", "PHA", "Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products Proposed Rule by FDA (RIN:0910-AG94); P.L. 110 -85 relating to Risk Evaluation and Mitigation Strategy programs.", "HOUSE OF REPRESENTATIVES,SENATE", 30000, null, 0, 0, "2014-10-14T15:57:55.680000-04:00"], [1585892, "7672d2b0-3370-4a85-929e-4eaa5dffa7c4", "Q3", "UNIVERSITY OF IOWA", 49191, "UNIVERSITY OF IOWA", 2014, "third_quarter", "PHA", "Increased appropriations for systems to shorten the time between development of a drug and its release to the public\nFDA reform as it relates to drug development and research         \nCollaborative research on drug development                                \nHuman factors research related to neuropharmaceuticals", "Agriculture, Dept of (USDA),Centers For Medicare and Medicaid Services (CMS),Defense, Dept of (DOD),Federal Emergency Management Agency (FEMA),Health & Human Services, Dept of (HHS),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE,Transportation, Dept of (DOT)", null, 85562, 0, 0, "2014-10-14T16:19:10.483000-04:00"], [1585978, "cc1e2be8-e919-49c3-bf10-d756304fb08c", "Q3", "ABRAHAM & ROETZEL, LLC", 400954757, "MATCHRX", 2014, "third_quarter", "PHA", "Drug Quality and Security Act.", "Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE", 10000, null, 0, 0, "2014-10-14T17:05:32.357000-04:00"], [1586043, "7d35e459-e487-4eea-9359-933cfb2c45a6", "Q3", "MR. GALEN RESER", 401055978, "PERRIGO INC (THROUGH FTI GOVERNMENT AFFAIRS)", 2014, "third_quarter", "PHA", "Repeals a requirement enacted into law as part of the PPACA of 2010 that requires consumers to obtain a prescription in order to utilize their FSA's and HSA's to purchase over-the-counter OTC medicines, H.R. 2835, \"Restoring Access to Medication Act of 2013.\" FDA's proposed changes to generic drug labeling. FDA's proposed Infant Formula regulations. House Energy and Commerce 21st Century Cures Initiative.", "HOUSE OF REPRESENTATIVES,SENATE", 10000, null, 0, 0, "2014-10-14T18:16:48.977000-04:00"], [1586094, "f80d3fe0-976b-4ada-af5a-8be83ade1b89", "Q3", "RUBICON ADVISORS, LLC", 315091, "TEVA PHARMACEUTICALS USA", 2014, "third_quarter", "PHA", "Patent Settlements H.R. 1432, Generic Biologies S H.R. 1695, H.R. 5629, Physican Payment Sunshine Act S 2029, Patent Reform H.R. 1908, Import Safety Act H.R. 3100\nAffodable Health Choices Act", "HOUSE OF REPRESENTATIVES,SENATE", 120000, null, 0, 0, "2014-10-14T22:39:06.887000-04:00"], [1586095, "402512e2-e435-40ce-aa4d-e4de16e3a95a", "Q3", "RUBICON ADVISORS, LLC", 315091, "ALLIANCE TO PREVENT THE ABUSE OF MEDICINES", 2014, "third_quarter", "PHA", "Prescription Drug Abuse Policy", "HOUSE OF REPRESENTATIVES,SENATE", 105000, null, 0, 0, "2014-10-14T22:44:07.857000-04:00"], [1586096, "92f2ea62-07ce-46e2-aacc-442f380f23f4", "3T", "RUBICON ADVISORS, LLC", 315091, "BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.", 2014, "third_quarter", "PHA", "Physician Payment Sunshine Act S 2029\nPatent Settlements H.R. 14328 .316\nAffordable Healthcare Choices Act", "HOUSE OF REPRESENTATIVES,SENATE", 60000, null, 0, 1, "2014-10-14T22:47:08.843000-04:00"], [1586099, "f21ed720-cf2e-4c0d-b60a-8a6497871ce1", "Q3", "RUBICON ADVISORS, LLC", 315091, "COLLEGE OF AMERICAN PATHOLOGISTS", 2014, "third_quarter", "PHA", "Physician Payment rates, Electronic Health Records Incentives Program", "HOUSE OF REPRESENTATIVES,SENATE", 30000, null, 0, 0, "2014-10-14T22:56:14.377000-04:00"], [1586100, "2c09edc4-fd76-4636-9023-4aebff9d6e5d", "Q3", "RUBICON ADVISORS, LLC", 315091, "STATE MUTUAL INSURANCE COMPANY", 2014, "third_quarter", "PHA", "Pharmacy Compounding", "HOUSE OF REPRESENTATIVES,SENATE", 60000, null, 0, 0, "2014-10-14T22:59:15.177000-04:00"], [1586501, "030a362b-bc79-4d6f-94bb-20eb794f29cb", "Q3", "SCONSET STRATEGIES, LLC", 400794388, "FREEMAN ALLERGY, INC.", 2014, "third_quarter", "PHA", "Issues related to securing additional clinical trials nationally and internationally.", "HOUSE OF REPRESENTATIVES,SENATE", 20000, null, 0, 0, "2014-10-15T11:07:54.150000-04:00"], [1586880, "3eddf118-06cb-4411-a392-68fd1590addb", "Q3", "VALENTE & ASSOCIATES", 45983, "SAV-MOR FRANCHISING, INC.", 2014, "third_quarter", "PHA", "Medicare Part D", "HOUSE OF REPRESENTATIVES", 30000, null, 0, 0, "2014-10-15T14:15:38.147000-04:00"], [1586989, "3131cc7d-04fd-483e-9866-114142859409", "3A", "BROWN RUDNICK LLP", 287895, "AMNEAL PHARMACEUTICALS", 2014, "third_quarter", "PHA", "Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products Proposed Rule by FDA (RIN:0910-AG94); P.L. 110 -85 relating to Risk Evaluation and Mitigation Strategy programs.", "HOUSE OF REPRESENTATIVES,SENATE", 30000, null, 0, 0, "2014-10-15T14:42:07.597000-04:00"], [1587164, "d949be25-c821-4795-ba4e-7b123c4a906d", "Q3", "BROWN RUDNICK LLP", 287895, "EXELA HOLDINGS, LLC", 2014, "third_quarter", "PHA", "Implementation of P.L. 112-144 (FDA Safety and Innovation Act) and P.L. 113 - 54 (Drug Quality and Security Act); Issues relating to ANDA approval", "Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE", 30000, null, 0, 0, "2014-10-15T15:25:44.860000-04:00"], [1588066, "90aba804-470a-4c3e-96a3-54136069acd5", "Q3", "APOTEX CORP.", 310973, "APOTEX CORP.", 2014, "third_quarter", "PHA", "FDA proposed rule,Supplemental Applications Proposing Labeling Changes For Approved Drugs And Biological Products, Docket Number FDA-2013-N-0500, provisions relating to generic drug labeling changes;\n\nHR 5657, the Fair Acess for Safe and Timely Generics Act of 2014, provisions relating to the provision of brand drug products by brand manufacturers to generic manufacturers for development testing;\n\nFederal policy relating to issues affecting the generic drug industry within the House Energy and Commerce Committee's 21st Century Cures initiative;\n\nFederal policy relating to International Nonroprietary Names for Biosimilars; and,\n\nImplementation of Public Law 112-144 - The Food and Drug Administration Safety and Innovation Act, federal policy relating to provisions in Title 3 regarding generic drug user fees.", "HOUSE OF REPRESENTATIVES,SENATE", null, 130000, 0, 0, "2014-10-16T09:31:46.353000-04:00"], [1588476, "5d6f309b-7808-4915-ae12-4a8ea622ddbe", "Q3", "SANOFI US SERVICES INC.", 56838, "SANOFI US SERVICES INC", 2014, "third_quarter", "PHA", "General issues related to the 340B Federal Drug Pricing Program", "HOUSE OF REPRESENTATIVES,SENATE", null, 940000, 0, 0, "2014-10-16T11:18:08.343000-04:00"], [1588483, "1b815530-d438-4d40-bbd1-a4dfe87fbf7c", "Q3", "EXPRESS SCRIPTS, INC.", 294416, "EXPRESS SCRIPTS, INC.", 2014, "third_quarter", "PHA", "Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 1367); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); specialty pharmacy tiering restrictions (HR 460); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; policies placing restrictions on pharmacy benefit designissues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs).   General issues dealing with prescription drug abuse (HR 3392) including Medicare Lock-in programs.  General issues dealing with regulating pharmacy drug compounding (PDSQ Act);  S. 867 (and versions HR 4437, HR 4577), the Medicare Prescription Drug Program Integrity and Transparency Act.", "Centers For Medicare and Medicaid Services (CMS),Congressional Budget Office (CBO),Executive Office of the President (EOP),Federal Trade Commission (FTC),Food & Drug Administration (FDA),Government Accountability Office (GAO),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Internal Revenue Service (IRS),Labor, Dept of (DOL),Medicare Payment Advisory Commission (MedPAC),Office of Personnel Management (OPM),SENATE,White House Office", null, 500000, 0, 0, "2014-10-16T11:21:09.860000-04:00"], [1589017, "c8b3c246-79ce-497c-bff8-3c6f36ba8b4f", "Q3", "NOVO NORDISK INC.", 284790, "NOVO NORDISK INC.", 2014, "third_quarter", "PHA", "HR 3204, S. 959 Drug Quality and Security Act (track and trace supply chain provisions); issues regarding biosimilars; 340B", "Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE,U.S. Trade Representative (USTR),Veterans Affairs, Dept of (VA)", null, 910000, 0, 0, "2014-10-16T13:23:49.780000-04:00"], [1589376, "a06ab644-734c-4a77-a512-7dee5269d3a9", "Q3", "PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION", 31348, "PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION", 2014, "third_quarter", "PHA", "Provisions of PL 111-148 and PL 111-152 impacting Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market (essential health benefits, grandfathering, value-based insurance design, e-prescribing, PBM disclosure requirements, and medical loss ratio).\n\nRegulatory and proposed legislative changes to Medicare part D including pharmacy networks, classes of clinical concern, mail-service pharmacy, EGWP waivers, MTM expansion, long term care short-term fills, recovery audit contractors.  Implementation of changes to the definition of Average Manufacturer Price in Medicaid Issues related to the management of Medicaid prescription drug benefits Legislation to promote generic drugs.  Regulatory Implementation of the HITECH Act.   FDA issues related to the Prescription Drug User Fee Act (PDUFA) (generic user fees, pedigree, REMs); implementation of approval pathway for generic biologic drugs,  340B program.  Issues related to the compounding of certain drugs.  \n\nS. 77, Prescription Drug and Health Improvement Act\n\nS. 557, Medication Therapy Management Empowerment Act\n\nH.R. 460, Patients Access to Treatments Act\n\nH.R. 1188, Preserving Our Hometown Independent Pharmacies Act\n\nH.R. 1367, FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act\n\nH.R. 1024, Medication Therapy Management Empowerment Act\n\nS.867, Medicare Prescription Drug Program Integrity and Transparency Act\n\nH.R. 2960, Medicare Prescription Drug Integrity Act of 2013\n\nH.R. 4160, Keep the Promise to Seniors Act\n\nH.R. 4577, Ensuring Seniors Access to Local Pharmacies Act of 2014 to Medicare/Medicaid; Pharmacy; and Health Care General\n\nH.R. 4418, Expanding the Availability of Medicare Data Act to Medicare/Medicaid", "Administration for Children & Families (ACF),Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),SENATE", null, 788458, 0, 0, "2014-10-16T14:25:06.393000-04:00"], [1589431, "cf7d6ef2-4914-4664-864f-d32e41f704b3", "Q3", "CONSUMER HEALTHCARE PRODUCTS ASSOCIATION", 29403, "CONSUMER HEALTHCARE PRODUCTS ASSOCIATION", 2014, "third_quarter", "PHA", "Over-the-counter (OTC) medicines; Manufacturing and importation of OTC drugs; Mandatory recall authority of the FDA; Rx-to-OTC SwitchSupporting a process within FDA that ensures clarity and timely outcomes for the FDA, applicants and stakeholders, as well as utilizing existing technologies to further streamline the prescription-to-nonprescription switch application process without changing the existing clear distinction between prescription and nonprescription medicines.\n\nH.R. 4250/S. 2141 - Sunscreen Innovation Act.  Would require FDA to approve or deny new sunscreen ingredient applications under the \"time and extent\" application (TEA) process within a certain timeframe after submission; all sections.", "Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE", null, 220000, 0, 0, "2014-10-16T14:30:16.803000-04:00"], [1589486, "21725fa6-0294-47c9-a620-84e61e8d267b", "Q3", "CUBIST PHARMACEUTICALS, INC.", 40026226, "CUBIST PHARMACEUTICALS", 2014, "third_quarter", "PHA", "Implementation of the \"GAIN\" provisions/Title VIII of the Food and Drug Administration Safety and Innovation Act (FDASIA) - PL 112-144; antibiotic product development incentive, limited population antibiotic product (LPAD) and breakpoint legislation; HR 3742- the Antibiotic Development to Advance Patient Treatment Act of 2013; H.R. 4187 - Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act of 2014;antibiotic product incentives for possible inclusion in the House \"21st Century Cures\" effort", "HOUSE OF REPRESENTATIVES,SENATE", null, 450000, 0, 0, "2014-10-16T14:36:26.210000-04:00"], [1589696, "e247e962-a2ec-4354-8014-029e6f849c51", "Q3", "WHITMER & WORRALL, LLC", 292892, "PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA)", 2014, "third_quarter", "PHA", "Issues related to The Patient Protection and Affordable Care Act (Public Law 111  148)", "Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE", 30000, null, 0, 0, "2014-10-16T15:09:04.130000-04:00"], [1589749, "41906f9b-8c92-40c6-8a1d-cc26294a06be", "Q3", "PD FRAZER CONSULTING, INC.", 65998, "CANADA INTERNATIONAL PHARMACY ASSOCIATION", 2014, "third_quarter", "PHA", "Monitor the development of proposed bills about the importation of prescription drugs.", "HOUSE OF REPRESENTATIVES,SENATE", 40000, null, 0, 0, "2014-10-16T15:20:55.430000-04:00"], [1589825, "1aa503a1-e391-4caa-b699-73ce7875d7f5", "Q3", "NELSON MULLINS RILEY & SCARBOROUGH", 285871, "TRANSDERMAL THERAPEUTICS, INC.", 2014, "third_quarter", "PHA", "Issues related to Tricare reimbursements", "HOUSE OF REPRESENTATIVES,SENATE", 20000, null, 0, 0, "2014-10-16T15:36:26.217000-04:00"], [1590467, "a455fc83-f556-40f4-85ce-0d9a54fea95f", "Q3", "GREATER NEW YORK HOSPITAL ASSOCIATION", 16830, "GREATER NEW YORK HOSPITAL ASSOCIATION", 2014, "third_quarter", "PHA", "Reducing the costs of pharmaceuticals, medical devices, and supplies for consumers and health care providers, including implementation of the Drug Quality and Security Act (P.L.113-54) and P.L.112-144; support medical device pricing transparency and prohibition on medical device price \"gag clauses\"; preserving access to group purchasing organizations (GPOs) and protecting the GPO safe harbor; opposing the current HRSA guidance on the 340b drug pricing GPO exclusion (HRSA Release 2013-1); opposing taxes on mobile health applications (FDA mobile health guidance and regulatory risk-based framework, FDA-2011-D-0530, FDA-2014-N-0339); comments on regulations affecting point-of-use care for glucose monitoring systems (FDA-2013-D-1445); educating policy makers on hospital drug shortages and significant drug price increases; pharmaceutical labeling of generic drugs (FDA-2013-N-0500); legislation to create a comprehensive Medicare home infusion benefit (HR5435) - support; and comments on Medicare physician services pertaining to non-face-to face chronic care management services (CMS- 1612-P).", "Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Housing & Urban Development, Dept of (HUD),SENATE,White House Office", null, 270000, 0, 0, "2014-10-16T17:23:09.660000-04:00"], [1590598, "5f3d3b98-6990-49df-a9eb-aad3e98fb567", "Q3", "KAISER FOUNDATION HEALTH PLAN INC.", 21027, "KAISER FOUNDATION HEALTH PLAN INC", 2014, "third_quarter", "PHA", "HR 4095 & S 2002 - Online Pharmacy Safety Act: To amend the Federal Food, Drug and Cosmetic Act to improve the safety of Internet pharmacies.", "Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE", null, 130000, 0, 0, "2014-10-16T17:58:35.557000-04:00"], [1590655, "223e08f8-c622-4056-b111-95f35de4be1f", "Q3", "MR. THEODORE (TED) JONES", 20926, "COQUI RADIOPHARMACEUTICALS, CORP.", 2014, "third_quarter", "PHA", "American Medical Isotopes Production Act of 2012 that was contained in teh National Defense Authorization Act for Fiscal Year 2013  Acceleration of production on 99 MO using LEU (Low Enriched Uranium).", "HOUSE OF REPRESENTATIVES,SENATE", 49134, null, 0, 0, "2014-10-16T18:09:41.433000-04:00"], [1590743, "a80a223d-d087-44f6-bb70-eaec1fd4d3a3", "Q3", "CROSSROADS STRATEGIES, LLC", 400531586, "LUMARA HEALTH", 2014, "third_quarter", "PHA", "Implementation issues related to the Pharmaceutical Quality, Security, and Accountability Act (P.L. 113-54); H.R.3089, Compounding Clarity Act of 2013; FDA related issues-specifically pharmacy compounding.", "HOUSE OF REPRESENTATIVES,SENATE", 60000, null, 0, 0, "2014-10-16T19:02:50.517000-04:00"], [1590829, "377f40f4-128c-4335-8b3f-d80e73d62eba", "Q3", "GOVBIZ ADVANTAGE, INC.", 294234, "WHITE HOUSE CONSULTING (FOR SYMBIOMIX)", 2014, "third_quarter", "PHA", "GAIN Act qualification for a drug", "HOUSE OF REPRESENTATIVES,SENATE", 15000, null, 0, 0, "2014-10-16T21:31:16.523000-04:00"], [1591172, "3850842a-6b6d-4140-84d1-11867f161c83", "Q3", "BLUESTONE STRATEGIES, LLC", 400658980, "PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA)", 2014, "third_quarter", "PHA", "Pharmacy Act; Generic Brand Settlement; Generic Dispensing; Generic Biologics; and Specialty Drug Issues", "HOUSE OF REPRESENTATIVES,SENATE", 50000, null, 0, 0, "2014-10-17T09:19:28.847000-04:00"], [1591267, "001bd9cb-2c2b-4bea-b4ac-5fda62c9a7e9", "3A", "ACADEMY OF MANAGED CARE PHARMACY", 48793, "ACADEMY OF MANAGED CARE PHARMACY", 2014, "third_quarter", "PHA", "Biosimilar naming - supporting Congressional action to seek FDA decision on biosimiar naming and supporting FTC study of effect of naming on competition.", "Centers For Medicare and Medicaid Services (CMS),Federal Trade Commission (FTC),HOUSE OF REPRESENTATIVES,SENATE", null, 210000, 0, 0, "2014-10-17T09:49:53.887000-04:00"], [1591390, "8b160c56-3058-45d9-9a9c-d50da08d975b", "Q3", "NELSON MULLINS RILEY & SCARBOROUGH", 285871, "INDIVIOR (FORMERLY, RECKITT BENCKISER PHARMACEUTICALS, INC.)", 2014, "third_quarter", "PHA", "Any legislation and regulation relating to the treatment of opioid abuse", "HOUSE OF REPRESENTATIVES,SENATE", 10000, null, 0, 0, "2014-10-17T10:12:57.787000-04:00"], [1591405, "3b64878d-9971-4245-8185-d26a65d7f0f1", "3A", "NELSON MULLINS RILEY & SCARBOROUGH", 285871, "INDIVIOR (FORMERLY, RECKITT BENCKISER PHARMACEUTICALS, INC.)", 2014, "third_quarter", "PHA", "Any legislation and regulation relating to the treatment of opioid abuse", "HOUSE OF REPRESENTATIVES,SENATE", 20000, null, 0, 0, "2014-10-17T10:14:01.160000-04:00"], [1591572, "d9d15223-e94c-4dac-99fe-c39acfaad200", "Q3", "OREGON HEALTH & SCIENCE UNIVERSITY", 30291, "OREGON HEALTH & SCIENCE UNIVERSITY", 2014, "third_quarter", "PHA", "340b Drug Discount program for safety net hospitals", "Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE", null, 70000, 0, 0, "2014-10-17T10:48:57.610000-04:00"], [1591645, "416278ed-6c5c-43a3-80ce-54c905c2fdbf", "Q3", "AMERICAN COLLEGE OF EMERGENCY PHYSICIANS", 1967, "AMERICAN COLLEGE OF EMERGENCY PHYSICIANS", 2014, "third_quarter", "PHA", "H.R.3089 - Compounding Clarity Act\nH.R.3528 - National All Schedules Prescription Electronic Reporting Reauthorization Act of 2013\nS.1323 - Protecting Our Youth from Dangerous Synthetic Drugs Act of 2013", "HOUSE OF REPRESENTATIVES,SENATE", null, 291063, 0, 0, "2014-10-17T10:55:11.020000-04:00"], [1591715, "de0925fe-6d29-4f60-b1b0-5601cd5913b7", "Q3", "WILLIAMS AND JENSEN, PLLC", 41454, "PHARMACY SERVICES", 2014, "third_quarter", "PHA", "Regulations of compounding pharmacies.", "HOUSE OF REPRESENTATIVES,SENATE", 30000, null, 0, 0, "2014-10-17T11:01:27.960000-04:00"], [1591854, "ef53f374-cea9-4fc8-8c7d-ef09dd7bfc73", "Q3", "SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING", 35968, "SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING", 2014, "third_quarter", "PHA", "Pharmacy compounding of radiopharmaceuticals; The Drug Quality and Security Act (HR 3204).", "Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,Nuclear Regulatory Commission (NRC),Office of Science & Technology Policy (OSTP),SENATE", null, 80000, 0, 0, "2014-10-17T11:19:03.757000-04:00"], [1591877, "15306be3-480e-4953-aa25-b9b4fbb4e7b6", "Q3", "EMPIRE CONSULTING GROUP", 400703105, "PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA", 2014, "third_quarter", "PHA", "Issues relating to the Medicare Prescription Drug Act; 340B Drug Pricing Program.", "HOUSE OF REPRESENTATIVES", 40000, null, 0, 0, "2014-10-17T11:21:06.940000-04:00"], [1591960, "f7d315fb-913a-44f9-8082-cf9478ccc536", "Q3", "RED+BLUE STRATEGIES", 400693064, "HOSPIRA", 2014, "third_quarter", "PHA", "Issues related to creating a new marketplace for biosimilar medications in the United States.", "Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Office of Management & Budget (OMB)", 30000, null, 0, 0, "2014-10-17T11:31:07.360000-04:00"], [1592041, "1df8dedd-fd8c-40fb-a0f5-5def4708e8ed", "Q3", "340B HEALTH", 316434, "340B HEALTH", 2014, "third_quarter", "PHA", "FY15 Labor-HHS Appropriations, Orphan Drug Rule, 340B Drug Discount Program", "Centers For Medicare and Medicaid Services (CMS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE", null, 244928, 0, 0, "2014-10-17T11:43:44.490000-04:00"], [1592146, "6b7d0647-d461-4665-9583-39b715493bf0", "Q3", "UNIVERSITY HOSPITAL-NEWARK, NEW JERSEY", 401097063, "UNIVERSITY HOSPITAL-NEWARK, NEW JERSEY", 2014, "third_quarter", "PHA", "--Support grant funding for trauma and emergency medical services for trauma hospitals\n-- Support readmissions policy to include socioeconomic factors \n--340B Program support to maintain current level of funding and discounts \n\nFunding for trauma and emergency services grant to hospitals\nH.R. 4188 and S. 2501- Readmissions policies must include socioeconomic factors\nH.R. 1250/S. 1012-Medicare Audit Improvement Act", "Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE", null, 15860, 0, 0, "2014-10-17T11:53:45.587000-04:00"], [1592245, "9a0d21cf-7a80-4863-a417-868f3443d284", "Q3", "KOUNTOUPES DENHAM CARR & REID, LLC", 320918, "CONSUMER HEALTHCARE PRODUCTS ASSOCIATION", 2014, "third_quarter", "PHA", "General issues related to over the counter pharmaceuticals, potential legislation to implement real-time, stop-sale electronic tracking system for sales of medications containing pseudoephedrine in order to preserve consumer access to the ingredient common in popular cold and allergy medications, and opposition to prescription requirements.  FDA Review of the Over the Counter Review Monograph and related rulemaking; H.R.4502 Stop Meth Labs and Enhance Patient Access Act of 2014.", "Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office", 50000, null, 0, 0, "2014-10-17T12:04:03.480000-04:00"], [1592432, "35b9e477-396c-4f89-93b0-add66218301f", "Q3", "ANIMAL HEALTH INSTITUTE", 4037, "ANIMAL HEALTH INSTITUTE", 2014, "third_quarter", "PHA", "FDA approval process; Unlicensed veterinary biologicals: Categorical Exclusions from Environmental Risk Assessments, Issues related to illegal drug manufacturing under the guise of compounding, HR4023 & S2756 - Fairness to Pet Owners Act", "HOUSE OF REPRESENTATIVES,SENATE", null, 40000, 0, 0, "2014-10-17T12:25:24.427000-04:00"], [1592951, "572f780d-021c-4953-8fc4-f721f30d6e6a", "Q3", "MEHLMAN CONSULTING, INC.", 284950, "WALMART INC", 2014, "third_quarter", "PHA", "Discussion on implementation of Medicare Part D and the Affordable Care Act.", "HOUSE OF REPRESENTATIVES,SENATE", 90000, null, 0, 0, "2014-10-17T13:32:44.940000-04:00"], [1593107, "0bcd3a3b-ab63-4692-aab2-982aa4e85cf5", "Q3", "TCH GROUP, LLC", 51478, "SANOFI US SERVICES INC (FORMERLY KNOWN AS SANOFI-AVENTIS U S INC )", 2014, "third_quarter", "PHA", "General issues related to the 340B Federal Drug Pricing Program", "HOUSE OF REPRESENTATIVES,SENATE", 40000, null, 0, 0, "2014-10-17T13:48:25.350000-04:00"], [1593356, "323e3539-6371-4257-bb3e-90ba165ab50b", "Q3", "BLUECROSS BLUESHIELD OF TENNESSEE", 6440, "BLUECROSS BLUESHIELD OF TENNESSEE", 2014, "third_quarter", "PHA", "General Pharmacy Issues", "HOUSE OF REPRESENTATIVES,SENATE", null, 40000, 0, 0, "2014-10-17T14:13:52.953000-04:00"], [1593585, "6ac0f175-7ec6-4737-bde6-110270519c23", "Q3", "BUCHANAN INGERSOLL & ROONEY PC", 55291, "WOCKHARDT LTD", 2014, "third_quarter", "PHA", "Strategy development and implementation of federal government relations initiatives; HR 3742, Antibiotic Development to Advance Patient Treatment; FDA compliance issues; HR 1919, Drug Supply Chain Security Act", "HOUSE OF REPRESENTATIVES,SENATE", 40000, null, 0, 0, "2014-10-17T14:33:38.290000-04:00"], [1593657, "4dc9b6b9-90e9-497c-84d8-4e2514c24c0e", "Q3", "CAPITOL HILL CONSULTING GROUP", 72053, "ENDO PHARMACEUTICALS", 2014, "third_quarter", "PHA", "Ensuring Safe Access to Prescription Medication Act of 2014 (S.2825)", "HOUSE OF REPRESENTATIVES,SENATE", 40000, null, 0, 0, "2014-10-17T14:38:37.493000-04:00"], [1593683, "a6a8d319-98bb-4ef2-bde3-3f439442f8b1", "Q3", "BAKER DONELSON BEARMAN CALDWELL & BERKOWITZ", 5153, "GENERIC PHARMACEUTICAL ASSOCIATION", 2014, "third_quarter", "PHA", "Issues relating to biosimilar regulation", "HOUSE OF REPRESENTATIVES,SENATE", 40000, null, 0, 0, "2014-10-17T14:40:45.087000-04:00"], [1593810, "64806ec8-c9ed-45ea-9eb4-e98381a3c37d", "Q3", "HANCE SCARBOROUGH", 17443, "ALLIANCE OF INDEPENDENT PHARMACISTS - TEXAS", 2014, "third_quarter", "PHA", "Federal legislation affecting the practice of pharmacy, and FDA and DEA regulations of compounded drugs.", "HOUSE OF REPRESENTATIVES,SENATE", 10000, null, 0, 0, "2014-10-17T14:50:35.090000-04:00"], [1593935, "4f915521-d2e7-483d-abd5-bea7eb4c6f81", "Q3", "AMERICAN VETERINARY MEDICAL ASSOCIATION", 3630, "AMERICAN VETERINARY MEDICAL ASSOCIATION", 2014, "third_quarter", "PHA", "H.R. 1150 Preservation of Antibiotics for Medical Treatment Act\nS. 1256 Prevent Antibiotic Resistance Act\nH.R. 1528/S. 1171 Veterinary Medicine Mobility Act\nH.R. 4023 Fairness to Pet Owners Act\nAnimal Compounding\nVeterinary Feed Directive\nDiscussions with Congressional staff about DEA regulations impeding practice of veterinary medicine; seeking passage of legislation to change underlying statute (H.R. 1528)\nDiscussions with Congressional staff and FDA regarding the use of antimicrobials in feed producing animals, particularly with respect to H.R. 1150 (Preservation of Antibiotics for Medical Treatment Act), S. 1256 (Preventing Antibiotic Resistance Act), and FDA's strategy.\nDiscussions with Congressional staff, FDA and Government Accountability Office expressing the need for compounding of medications for use in animals. \nInquiries to and discussions with Congressional staff and Federal Trade Commission on veterinary pet prescriptions, particularly regarding H.R. 4023/S. 2756 (Fairness to Pet Owners Act)", "Agriculture, Dept of (USDA),Federal Trade Commission (FTC),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE", null, 210000, 0, 0, "2014-10-17T14:55:59.387000-04:00"], [1594046, "c0b5dea4-4293-4926-9fc7-5915ff2b4618", "3A", "AMERICAN VETERINARY MEDICAL ASSOCIATION", 3630, "AMERICAN VETERINARY MEDICAL ASSOCIATION", 2014, "third_quarter", "PHA", "H.R. 1150 Preservation of Antibiotics for Medical Treatment Act\nS. 1256 Prevent Antibiotic Resistance Act\nH.R. 1528/S. 1171 Veterinary Medicine Mobility Act\nH.R. 4023 Fairness to Pet Owners Act\nAnimal Compounding\nVeterinary Feed Directive\nDiscussions with Congressional staff about DEA regulations impeding practice of veterinary medicine; seeking passage of legislation to change underlying statute (H.R. 1528)\nDiscussions with Congressional staff and FDA regarding the use of antimicrobials in feed producing animals, particularly with respect to H.R. 1150 (Preservation of Antibiotics for Medical Treatment Act), S. 1256 (Preventing Antibiotic Resistance Act), and FDA's strategy.\nDiscussions with Congressional staff, FDA and Government Accountability Office expressing the need for compounding of medications for use in animals. \nInquiries to and discussions with Congressional staff and Federal Trade Commission on veterinary pet prescriptions, particularly regarding H.R. 4023/S. 2756 (Fairness to Pet Owners Act)", "Agriculture, Dept of (USDA),Federal Trade Commission (FTC),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE", null, 210000, 0, 0, "2014-10-17T15:03:14.657000-04:00"], [1594109, "8efbd9f0-3bef-4ee0-8642-16e5a3169779", "Q3", "BLUE CROSS AND BLUE SHIELD ASSOCIATION", 6358, "BLUE CROSS AND BLUE SHIELD ASSOCIATION", 2014, "third_quarter", "PHA", "Prescription Drugs", "Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),Office of Management & Budget (OMB),Office of Personnel Management (OPM),SENATE,Treasury, Dept of,White House Office", null, 1540000, 0, 0, "2014-10-17T15:08:04.893000-04:00"], [1594137, "40bd36fe-4f6c-4d16-a9fe-743ef88b1858", "Q3", "THORSEN FRENCH ADVOCACY LLC", 400599826, "ASTRAZENECA PHARMACEUTICALS LP", 2014, "third_quarter", "PHA", "Issues related to access to pharmaceuticals.", "HOUSE OF REPRESENTATIVES,SENATE", 30000, null, 0, 0, "2014-10-17T15:11:17.113000-04:00"], [1594182, "7406df1a-87e2-46c2-95e8-7000e59e7513", "Q3", "CAPITOL HILL CONSULTING GROUP", 72053, "PROFESSIONAL COMPOUNDING CENTERS OF AMERICA", 2014, "third_quarter", "PHA", "Pharmaceutical Compounding and Accountability Act (S.959)\nThe Compound Clarity Act (H.R.3089)\nThe Drug Quality and Security Act (H.R.3204)\nIssues related to implementation of the Compounding Quality Act", "Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE", 50000, null, 0, 0, "2014-10-17T15:13:24.520000-04:00"], [1594200, "9b9d12fb-f0e3-45e7-a247-78ea5aa3e383", "Q3", "BROWN RUDNICK LLP", 287895, "HOSPIRA, INC.", 2014, "third_quarter", "PHA", "Issues relating to drug shortages; Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products Proposed Rule by FDA (RIN:0910-AG94).", "HOUSE OF REPRESENTATIVES,SENATE", 50000, null, 0, 0, "2014-10-17T15:14:34.880000-04:00"], [1594293, "9774d8c9-c2d7-419c-bf6e-8b8ef4966a1b", "Q3", "BROWN RUDNICK LLP", 287895, "APOTEX CORPORATION", 2014, "third_quarter", "PHA", "Issues relating to Risk Evaluation and Mitigation Strategy programs; Generic Drug User Fee Amendments of 2012 (GDUFA); Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products Proposed Rule by FDA (RIN:0910-AG94).", "HOUSE OF REPRESENTATIVES,SENATE", 50000, null, 0, 0, "2014-10-17T15:21:56.507000-04:00"], [1594385, "66ba298f-1229-491a-8f0d-1aef38ee65e0", "Q3", "BROWN RUDNICK LLP", 287895, "HEALTHCARE DISTRIBUTION ALLIANCE F/K/A HEALTHCARE DISTRIBUTION MANAGEMENT ASSOC", 2014, "third_quarter", "PHA", "H.R. 4709 - Ensuring Patient Access and Effective Drug Enforcement Act; S. 2862-The Regulatory Transparency, Patient Access, and Effective Drug Enforcement Act of 2014; H.R. 4299 - Improving Regulatory Transparency for New Medical Therapies Act; Implementation of P.L. 113 - 54 (Drug Quality and Security Act)", "HOUSE OF REPRESENTATIVES,SENATE", 60000, null, 0, 0, "2014-10-17T15:27:17.587000-04:00"], [1594448, "57e44d4f-fe93-4b6f-9905-0188a9f820ad", "Q3", "CAPITOL HILL CONSULTING GROUP", 72053, "WELLNESS PHARMACY", 2014, "third_quarter", "PHA", "Pharmaceutical Compounding and Accountability Act (S.959)\nThe Compound Clarity Act (H.R.3089)\nThe Drug Quality and Security Act (H.R.3204)\nIssues related to implementation of the Compounding Quality Act", "HOUSE OF REPRESENTATIVES,SENATE", 10000, null, 0, 0, "2014-10-17T15:31:16.057000-04:00"], [1594479, "8fd833e4-d5f2-4581-874b-88e3fa10c674", "Q3", "BROWN RUDNICK LLP", 287895, "PRIME THERAPEUTICS", 2014, "third_quarter", "PHA", "Issues relating to prescription drug abuse and diversion; HR 4577 - Ensuring Seniors Access to Local Pharmacies Act of 2014", "Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE", 30000, null, 0, 0, "2014-10-17T15:32:38.743000-04:00"], [1594549, "0b313d8e-bfba-4378-86a0-6d98d183f83f", "Q3", "AMERICAN ACADEMY OF FAMILY PHYSICIANS", 1342, "AMERICAN ACADEMY OF FAMILY PHYSICIANS", 2014, "third_quarter", "PHA", "HR 3528, National All Schedules Prescription Electronic Reporting Reauthorization Act, Prevent opiod abuse, encourage adequate pain management; Support reauthorization of NASPER to provide immediate information about perscription use.\nS. 2529, National All Schedules Prescription Electronic Reporting Reauthorization Act, Prevent opiod abuse, encourage adequate pain management;  Support reauthorization of NASPER to provide immediate information about perscription use.", "Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE,Veterans Affairs, Dept of (VA),White House Office", null, 1924466, 0, 0, "2014-10-17T15:36:37.480000-04:00"], [1594558, "9fb775fd-6f92-490d-8dc6-e9c174161631", "Q3", "ARNOLD & PORTER KAYE SCHOLER LLP", 4301, "INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS", 2014, "third_quarter", "PHA", "Issues related to the regulation of the practice of pharmacy compounding.", "HOUSE OF REPRESENTATIVES,SENATE", 50000, null, 0, 0, "2014-10-17T15:36:39.793000-04:00"], [1594606, "0c6f9a13-d7be-4db9-81f6-e8335d1be403", "Q3", "BROWN RUDNICK LLP", 287895, "MEDTRONIC INC", 2014, "third_quarter", "PHA", "S. 2825 relating to the delivery of a controlled substance by a pharmacy to a practitioner", "HOUSE OF REPRESENTATIVES,SENATE", 20000, null, 0, 0, "2014-10-17T15:38:58.967000-04:00"], [1594617, "f28d5eb3-dd69-4b2d-ab18-08f89d5c0675", "Q3", "CAPITOL HILL CONSULTING GROUP", 72053, "PURDUE PHARMA LLP", 2014, "third_quarter", "PHA", "Controlled Drug Substances Act (21 USC 13)\nStop Tampering of Prescription Pills Act of 2013 (H.R. 486)", "Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE", 50000, null, 0, 0, "2014-10-17T15:39:45.560000-04:00"], [1594678, "c56633ad-de59-4e25-90ed-0102b861ea1e", "Q3", "BROWN RUDNICK LLP", 287895, "ZYDUS PHARMACEUTICALS USA INC.", 2014, "third_quarter", "PHA", "Issues relating to FDA generic drug approval; Generic Drug User Fee Amendments of 2012 (GDUFA)", "HOUSE OF REPRESENTATIVES", 30000, null, 0, 0, "2014-10-17T15:44:16.187000-04:00"], [1594787, "209d9284-9654-4a00-872f-c01f902d2950", "Q3", "AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS", 3457, "AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS", 2014, "third_quarter", "PHA", "Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, and implementation of the Drug Quality and Security Act. Contact concerning HRSA oversight of 340B drug discount program. Contact concerning the Drug Quality and Security Act, H.R. 3204, all titles. Communication with the FDA on the labeling of generic medications and biosimilars. Communication with FTC on biosimilars.", "Centers For Medicare and Medicaid Services (CMS),Federal Trade Commission (FTC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE", null, 250000, 0, 0, "2014-10-17T15:54:21.893000-04:00"]], "truncated": false, "filtered_table_rows_count": 235, "expanded_columns": [], "expandable_columns": [[{"column": "filing_uuid", "other_table": "lobbying_filings_raw", "other_column": "filing_uuid"}, "registrant_name"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "units": {}, "query": {"sql": "select id, filing_uuid, filing_type, registrant_name, registrant_id, client_name, filing_year, filing_period, issue_code, specific_issues, government_entities, income_amount, expense_amount, is_no_activity, is_termination, received_date from lobbying_activities where \"filing_period\" = :p0 and \"filing_year\" = :p1 and \"issue_code\" = :p2 order by filing_year desc limit 101", "params": {"p0": "third_quarter", "p1": "2014", "p2": "PHA"}}, "facet_results": {"issue_code": {"name": "issue_code", "type": "column", "hideable": false, "toggle_url": "/lobbying/lobbying_activities.json?filing_period=third_quarter&filing_year=2014&issue_code=PHA", "results": [{"value": "PHA", "label": "PHA", "count": 235, "toggle_url": "https://www.pawtectors.org/lobbying/lobbying_activities.json?filing_period=third_quarter&filing_year=2014", "selected": true}], "truncated": false}, "filing_year": {"name": "filing_year", "type": "column", "hideable": false, "toggle_url": "/lobbying/lobbying_activities.json?filing_period=third_quarter&filing_year=2014&issue_code=PHA", "results": [{"value": 2014, "label": 2014, "count": 235, "toggle_url": "https://www.pawtectors.org/lobbying/lobbying_activities.json?filing_period=third_quarter&issue_code=PHA", "selected": true}], "truncated": false}, "filing_period": {"name": "filing_period", "type": "column", "hideable": false, "toggle_url": "/lobbying/lobbying_activities.json?filing_period=third_quarter&filing_year=2014&issue_code=PHA", "results": [{"value": "third_quarter", "label": "third_quarter", "count": 235, "toggle_url": "https://www.pawtectors.org/lobbying/lobbying_activities.json?filing_year=2014&issue_code=PHA", "selected": true}], "truncated": false}}, "suggested_facets": [{"name": "is_termination", "toggle_url": "https://www.pawtectors.org/lobbying/lobbying_activities.json?filing_period=third_quarter&filing_year=2014&issue_code=PHA&_facet=is_termination"}, {"name": "received_date", "type": "date", "toggle_url": "https://www.pawtectors.org/lobbying/lobbying_activities.json?filing_period=third_quarter&filing_year=2014&issue_code=PHA&_facet_date=received_date"}], "next": "2014,1594787", "next_url": "https://www.pawtectors.org/lobbying/lobbying_activities.json?filing_period=third_quarter&filing_year=2014&issue_code=PHA&_next=2014%2C1594787&_sort_desc=filing_year", "private": false, "allow_execute_sql": true, "query_ms": 1982.3661639820784, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}